Keytruda is a brand name for the drug pembrolizumab, which is a type of immunotherapy that helps the immune system fight cancer cells [3]. According to Drug Patent Watch, the patent for Keytruda will expire on June 30, 2028 [1]. After the patent expires, generic versions of the drug may become available, which could potentially lower the cost of the drug. However, it is important to note that the availability and cost of generic versions of Keytruda will depend on various factors, including regulatory approval and market competition.

In the meantime, the cost of Keytruda can be quite high. The official Keytruda website offers financial support programs to help eligible patients afford the drug [2]. These programs include co-pay assistance, patient assistance, and free drug programs. Eligibility requirements and benefits vary depending on the program, so it is recommended to check the website for more information.

It is also worth noting that Keytruda is not always used as a standalone treatment. According to a Cancer Currents blog post by the National Cancer Institute, Keytruda is sometimes used in combination with other treatments, such as chemotherapy, for certain types of cancer [3]. The cost of treatment will depend on various factors, including the type and stage of cancer, the treatment plan, and insurance coverage.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytruda.com/financial-support/
[3] https://www.cancer.gov/news-events/cancer-currents-blog/2023/neoadjuvant-immunotherapy-only-treatment